Anti-viral Brincidofovir Being Tested in Africa for Ebola

[Wally]

Brincidofovir is an experimental anti-viral. It is the oral form of the anti-viral Cidofovir (Vistide). Cidofovir has been used as a treatment for some patients diagnosed with ME/CFS and it is currently being tested in Africa as a possible treatment for Ebola.

"The first antiviral drug, known as brincidofovir, is being tested by Oxford University at a separate site in Liberia, though researchers have not revealed exactly where.

The drug comes in tablet form and needs to be taken twice a week for two weeks. The drug works by interfering with the way the virus multiplies within healthy human cells.

It will be given to 140 patients, with their consent, and doctors will compare their survival rates against those who were not treated."

Read more: http://www.dailymail.co.uk/news/art...try-bring-outbreak-control.html#ixzz3IyzjwrBr

For more information about Brincidofovir, see the links below.

1) http://jid.oxfordjournals.org/content/202/10/1492.full
2) http://phoenixrising.me/archives/6108
3) http://www.cortjohnson.org/treating...onic-fatigue-syndrome-mecfs-treatment/cmx001/
4) http://hhv-6foundation.org/clinicians/hhv-6-treatment
5) http://books.google.com/books?id=oo...onepage&q=brincidofovir CMX001 ME CFS&f=false
6) http://www.wncn.com/story/26438036/chimerix-experimental-drug-shows-promise-in-fighting-ebola-virus
7) http://www.medfrontiers.com/news197.html
8) Politics at play for anti-viral drug manufacturers? - http://www.forbes.com/sites/rickung...g-deal-obama-administrations-next-solyndra/2/ (See also, http://www.upmchealthsecurity.org/our-work/publications/smallpox-fact-sheet)
9) http://ir.chimerix.com/releasedetail.cfm?releaseid=868499

 

[Wally]

More news reports about Brindofovir being used to treat Ebola.

http://www.forbes.com/sites/davidkr...or-using-brincidofovir-bcv-in-ebola-patients/

"On Tuesday, Dr. Craig Spencer, 33, was released from Bellevue Hospital in Manhattan and declared free of the Ebola virus infection that the physician contracted while treating disease victims in the West African country of Guinea. . . . In addition to supportive care, Dr. Spencer received a blood transfusion from Ebola survivor, Nancy Writebol, and the antiviral drug, brincidofovir (BCV)."

See also, 11/13/2014 News Release from Chimerix about Brincidofovir clinical trial in Africa in collaboration with the University of Oxford with funding from the Wellcome Trust.
http://ir.chimerix.com/releasedetail.cfm?ReleaseID=882888

(Edit -The Forbes article linked above provides some insight into how Brincidofovir, developed for DNA viruses, may also be effective for RNA viruses like Ebola.)

 

[heapsreal]

Love to try it,
im sure it will be affordable for most of us????

 

[heapsreal]

it also mentions another experimental drug called favipiravir which seems to have a broad range of action and even works on enteroviruses, something dr chia has been waiting for??

Favipiravir, also known as T-705 or Avigan, is an experimental anti-viral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. Like some other experimental antiviraldrugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. Favipiravir is active against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses,bunyaviruses and alphaviruses.[1] Activity against enteroviruses [2] and Rift Valley fever virus has also been demonstrated.[3]

The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them.[1]

In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.[4] The drug appears to be effective in a mouse model ofEbola virus disease.[5][6][7] During the 2014 West Africa Ebola virus outbreak, Japan offered to supply the drug if requested by the WHO.[8] On 4 October 2014, it was reported that a French nurse who contracted Ebola while volunteering for MSF in Liberia during the Ebola virus epidemic in West Africa recovered after receiving a treatment of favipiravir.[9]

Though the efficiency of this drug in curing human Ebola infection is still unclear, some positive results are emerging in animal experiments.

Professor Shiraki Kimiyasu from University of Toyama Graduate School have partnered with Toyama Chemical and conducted experiments on the effect of favipiravir against Ebola virus infection in mice. In the interview with local newspaper, he commented that "earlier administration of favipiravir is crucial to protect the life of an Ebola infected patient; it determines the survival rate."[10]

According to Shiraki, five mice infected with Ebola virus were administrated with favipiravir after sixth day of infection and all subject have survived after eighth day since administration of the drug. Meanwhile, in the other group of mice, which were administrated on the eighth day after infection, no mice have survived in the end, though some mice showed signs of improvement. Shiraki admitted there might be some differences between human and mouse, and added "I believe it's strongly preferable that in human Ebola infection, administration of favipiravir should start, at latest, on the day of onset."[10]

http://en.wikipedia.org/wiki/Favipiravir